Efficacy of switching from existing anti-vascular endothelial growth factor drugs to ranibizumab biosimilar in neovascular age-related macular degeneration
Switching from aflibercept to ranibizumab BS effectively maintained disease stability and cytokine balance in eyes with nAMD. These findings support ranibizumab BS as a viable and cost-effective alternative for long-term treatment.
Authors
- Hikaru Ota (ORCID: https://orcid.org/0009-0004-3052-9391)
- Koji M. Nishiguchi (ORCID: https://orcid.org/0000-0001-5987-4421)
- Hiroki Kaneko (ORCID: https://orcid.org/0000-0003-0731-6465)
- Jun Takeuchi (ORCID: https://orcid.org/0000-0002-8998-1102)
- Katsuhiro Tamura
- Ryo Nonogaki
Institutions
- Kyorin University (JP)
- Hamamatsu University School of Medicine (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Japanese Journal of Ophthalmology
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1007/s10384-025-01224-0
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Nagoya University